BioTryp Therapeutics, a University of Cambridge spin-out company, is developing novel therapies to treat infections. BioTryp's novel class of small molecules inhibit bacterial biofilms, nipping an infection in the bud. Biofilms are communities of pathogens enclosed in a protective matrix. Biofilms are linked with treatment failure and repeated infections. By targeting bacteria's key defence mechanism, BioTryp's technology has the potential to revolutionise how we treat infection, providing a much needed alternative to traditional antibiotic treatments.